Monitor for any reverse stock split announcement or capital raise as the company works toward the November 30 deadline. If the stock fails to recover above $1.00, delisting risk increases significantly, which could trigger further selling pressure in both JSPR and JSPRW warrants.
Price Chart
Executive Summary
Jasper Therapeutics received a Nasdaq deficiency notice on June 3, 2026, because its common stock bid price closed below $1.00 for 30 consecutive business days, violating Listing Rule 5550(a)(2). The company has until November 30, 2026 to regain compliance by closing at $1.00 or higher for 10 consecutive days, or it may seek a second 180-day cure period. Failure to cure could lead to delisting, which would severely reduce institutional ownership and liquidity for both JSPR and JSPRW.
Key Facts
- Nasdaq notice received June 3, 2026 for bid price below $1.00 for 30 consecutive business days
- Initial compliance period ends November 30, 2026 (180 calendar days)
- To regain compliance, bid price must close at $1.00 or more for 10 consecutive business days
- If not cured by Nov 30, company may be eligible for an additional 180-day period if it meets other listing standards
- Company may consider a reverse stock split to cure the deficiency
- Both JSPR common stock and JSPRW warrants continue trading on Nasdaq Capital Market for now
Financial Impact
Delisting risk for a pre-revenue biotech with $0 market cap — loss of Nasdaq listing would severely impair liquidity and institutional access
Risk Factors
- Failure to regain compliance by November 30, 2026 could lead to delisting
- Even if eligible for a second 180-day period, Nasdaq staff may deny continued listing
- Reverse stock split could be necessary but may not stabilize the stock price
- Delisting would severely reduce liquidity and institutional ownership
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-066782 |
| Document: 0001213900-26-066782-index-headers.html | 0001213900-26-066782 |
| Document: 0001213900-26-066782-index.html | 0001213900-26-066782 |
| Document: 0001213900-26-066782.txt | 0001213900-26-066782 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 9, 2026 19w ago | 8-K | $0.0134 $0.009200 | ▲ +31.34% | ▲ +37.92% | — |
Jun 1, 2026 21w ago | 8-K | $0.0204 $0.009800 | ▲ +51.96% | ▲ +53.19% | — |
May 21, 2026 22w ago | 8-K | $0.0204 $0.0138 | ▼ −32.35% | ▼ −35.54% | — |
May 14, 2026 23w ago | 8-K | $0.0204 $0.0144 | ▲ +29.41% | ▲ +33.93% | — |
Mar 30, 2026 30w ago | 8-K | $0.0204 $0.0135 | ▼ −33.82% | ▼ −46.21% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers